Biotechnology company Threshold Pharmaceuticals Inc (THLD) Wednesday reported promising results from the clinical trials of the Phase 1 study of TH-302 in patients with advanced leukemia conducted at MD Anderson's Cancer Center in Houston, Texas.
The company stated that Thirty-two patients with either acute myelogenous leukemia, or AML, or acute lymphoblastic leukemia, or ALL, have been enrolled in the trial.
Efficacy assessments have demonstrated TH-302 activity in multiple subjects with relapsed/refractory AML and ALL as evidenced by stabilization or reduction of bone marrow and peripheral blast counts.
Commenting on the results, Dr. Marina Konopleva, M.D., Associate Professor in the Department of Leukemia at MD Anderson Cancer Center, said, ""With the establishment of the MTD, we look forward to better defining the safety and efficacy of single agent TH-302 in patients with advanced leukemias."
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.